<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455844</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-API-NKPL66-CT-PII</org_study_id>
    <nct_id>NCT01455844</nct_id>
  </id_info>
  <brief_title>TRIal For Efficacy of Capre on hyperTriglyceridemiA</brief_title>
  <acronym>TRIFECTA</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acasti Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acasti Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for&#xD;
      12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high&#xD;
      hypertriglyceridemia as compared to a placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (%) change in triglycerides between the baseline and the 12-week assessment visit.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in triglycerides between the baseline and the 12-week assessment visit.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">387</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>CaPre 1.0g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CaPre 2.0g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CaPre (TM)</intervention_name>
    <description>CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.</description>
    <arm_group_label>CaPre 1.0g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CaPre (TM)</intervention_name>
    <description>CaPre™ 2.0g daily for 12 weeks</description>
    <arm_group_label>CaPre 2.0g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults aged 18 to 75 years.&#xD;
&#xD;
          -  Fasting plasma levels of TG ≥ 2.28 and &lt;10 mmol/L (200 and 877 mg/dL) on two occasions&#xD;
             within 2 weeks (screening and pre-randomization visits).&#xD;
&#xD;
          -  Patients who are currently not on pharmacotherapy for hyperlipidemia and according to&#xD;
             the judgement of the physician and Canadian Guidelines for the Diagnosis and Treatment&#xD;
             of Dyslipidemia initiation of drug therapy is not indicated for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Patients currently treated with statins and according to the judgement of the&#xD;
             physician and the Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia&#xD;
             a change in their current drug regimen is not indicated for the duration of the study.&#xD;
&#xD;
          -  Patients treated with statin must be on stable dose for at least 6 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Patients are willing follow the NCEP Step 1 Diet (see Appendix 4) for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Female participants of childbearing potential (i.e. not surgically sterilized or&#xD;
             post-menopausal greater than one year) must have negative serum pregnancy test and&#xD;
             must be using an effective birth control method, defined as:&#xD;
&#xD;
               1. continuous use of oral or long acting injected contraceptive for at least 2&#xD;
                  months prior to study entry, or;&#xD;
&#xD;
               2. use of an intra-uterine device or implantable contraceptive, or;&#xD;
&#xD;
               3. use of double barrier methods of birth control&#xD;
&#xD;
          -  Patients are at least 80% compliant with the study medication during the placebo lead&#xD;
             in phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concomitant medication which in the opinion of the investigator would preclude the&#xD;
             patient from successfully participating in the study.&#xD;
&#xD;
          -  Women who are pregnant or that are breast feeding.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days from initiation of the study.&#xD;
&#xD;
          -  Participants with a high risk for cardiovascular disease; (The definition of high-risk&#xD;
             individuals will follow that of the 2009 Canadian Guidelines and include a) FRS &gt;= 20%&#xD;
             10-year risk; b) All patients with uncontrolled diabetes (DCA guidelines) and c)&#xD;
             Evidence of atherosclerosis -when this evidence was ascertained when clinically&#xD;
             indicated);&#xD;
&#xD;
          -  Systolic blood pressure &gt;140 mmHg and/or diastolic blood pressure &gt;90 mmHg. In&#xD;
             diabetic patients, systolic blood pressure &gt; 130 mmHg and/or diastolic blood pressure&#xD;
             &gt; 90 mmHg.&#xD;
&#xD;
          -  History of stroke, intermittent claudication or transient ischemic attack.&#xD;
&#xD;
          -  Known unstable (uncontrolled) cardiac disease , within the last 6 months.&#xD;
&#xD;
          -  Patient with a clinically significant abnormal ECG at screening.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus, with HbA1c &gt; 7.0%.&#xD;
&#xD;
          -  Known diagnosis of hypoglycemia.&#xD;
&#xD;
          -  Evidence of active renal disease indicated by a fasting estimated glomerular&#xD;
             filtration rate (eGFR) of &lt; 60 ml/min per 1.73 m2.&#xD;
&#xD;
          -  Increased plasma levels (&gt;ULN) of amylase (as per respective lab upper limits) and /&#xD;
             or lipase (&gt;160 IU/L) or any indication of pancreatitis pancreatitis (increased&#xD;
             alcohol consumption, gallstones).&#xD;
&#xD;
          -  History of pancreatitis.&#xD;
&#xD;
          -  Use of any lipid lowering medication other than statins or ezetimibe(e.g niacin,&#xD;
             fibrates) and/or lipid lowering NHP within 6 weeks prior to the screening visit.&#xD;
&#xD;
          -  Intake of &gt; 2 servings per week of fish or regimented use of fish oil/omega-3&#xD;
             supplements within 6 weeks prior to the screening visit.&#xD;
&#xD;
          -  Known HIV or Hepatitis B or C positive.&#xD;
&#xD;
          -  Patients with uncontrolled asthma as defined by the 2010 Consensus Summary of the&#xD;
             Canadian Thoracic Society.&#xD;
&#xD;
          -  Known seafood allergy or allergy to any of the medicinal or non-medicinal ingredients&#xD;
             of the study medication and placebo, including:&#xD;
&#xD;
               1. Omega-3 fatty acids (including EPA and DHA)&#xD;
&#xD;
               2. Phospholipids (mainly phosphatidylcholine)&#xD;
&#xD;
               3. Astaxanthin&#xD;
&#xD;
               4. Microcrystalline cellulose&#xD;
&#xD;
          -  Coagulopathy or on anticoagulants. Platelet aggregation inhibitors (such as aspirin or&#xD;
             clopidogrel but not heparin) are permitted in the study; patients taking both aspirin&#xD;
             and clopidogrel are not permitted in the study.&#xD;
&#xD;
          -  Unable or unwilling to comply with the protocol.&#xD;
&#xD;
          -  Patient reported weight was not stable for the past 6 months (within 3kg variation).&#xD;
&#xD;
          -  Consumption of more than 14 standard alcoholic drinks a week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Genest, MD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Division, MUHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Research</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research Group</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CookMed Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Line Medical Services Ltd</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White Hills Medical Clinic</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scisco Clinical Research</name>
      <address>
        <city>Cornwall</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corunna Medical Resarch Centre</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD-Medical Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Source Unique Research Inc.</name>
      <address>
        <city>Hawkesbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagot Street Medical Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milestone Research</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC, Siebens-Drake Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S &amp; G Clinical Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDA Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Medical Phoenix</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Road Diagnostic Clinic and Medical Centre</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarnia Institute of Clinical Research</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scarborough Cardiology Research</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Source Unique Research Inc.</name>
      <address>
        <city>Dollard Des-Ormeaux</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLIN DE MED Grand-Mere</name>
      <address>
        <city>Grand-Mere</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Montreal Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montréal (IRCM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dynamik Research Inc.</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kells Medical Research</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Maladies Lipidiques de Quebec Inc</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale St-Louis</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre médical-des-carrières</name>
      <address>
        <city>St-Marc-des-carrières</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro-Recherche Inc.</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

